Disease relevance of Recainam

• Recainam, a potent new antiarrhythmic agent: effects on complex ventricular arrhythmias [1].
• The antiarrhythmic efficacy and safety of intravenous recainam, a newly synthesized compound displaying potent class I antiarrhythmic activity, were tested in 10 hospitalized patients with frequent (greater than 30/h) complex ventricular ectopic beats [1].
• Electrophysiologic effects and efficacy of recainam for sustained ventricular tachycardia [2].
• Recainam was administered as a loading dose of 3 mg/kg/40 minutes followed by a continuous infusion of 0.9 mg/kg/hr for 23 hours and 20 minutes to ten patients with cardiac disease and frequent PVCs (more than 30/hr) [3].
• Based on these data, recainam can be safely administered as a loading dose followed by a continuous infusion in patients with stable cardiac disease without significant ventricular dysfunction [3].

High impact information on Recainam

• The data indicate that the electrophysiologic profile of recainam in isolated cardiac muscle is consistent with the overall effects of class IC agents without having an effect on the slow calcium channel [4].
• Recainam induced a concentration- and frequency-dependent decrease in the maximal rate of rise of the phase 0 of the action potential (Vmax), action potential amplitude and overshoot potential, with little or no change in the effective refractory period except in Purkinje fibers, in which it was markedly reduced [4].
• OBJECTIVES: To investigate the pharmacokinetics and pharmacodynamics of recainam, an investigational class I antiarrhythmic agent, in subjects with various degrees of renal function [5].
• Recainam (100 microM) reduced IK by only 7 (SEM 3)% after 20-30 min exposure and by 19% after an 80 min exposure (IC50 > 400 microM) [6].
• The absolute bioavailability of orally administered recainam increased from 73% for the 200 mg dose to 81% and 84% for the 400 and 800 mg doses, respectively [7].

Chemical compound and disease context of Recainam

• The antiarrhythmic efficacy and safety of oral recainam hydrochloride, a newly synthesized compound, were assessed during a 2-part study of 12 patients with frequent (at least 30/hour) ventricular premature complexes (VPCs) [8].
• Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction [9].

Biological context of Recainam

• Cardiac electrophysiology of the antiarrhythmic agent recainam (Wy-42,362) in anesthetized dogs: relation to plasma and myocardial concentrations [10].
• The results showed no change in mean arterial pressure, but heart rate increased slightly by 4 beats/min following recainam infusion [11].
• The curves relating membrane potential and Vmax in preparations stimulated at a low frequency (0.01 Hz) were not shifted by 10(-4) M recainam [12].
• The plasma Cmax and AUC of recainam were virtually identical after single or multiple (21 day) oral doses in dogs [13].

Anatomical context of Recainam

• The effects of recainam (Wy 42,362) on transmembrane action potentials were examined in isolated rabbit right ventricular papillary muscles [12].

Associations of Recainam with other chemical compounds

• The effects of an intravenous infusion of the new class III antiarrhythmic drug N-acetylprocainamide (30 mg/kg over 15 min) and the class Ic antiarrhythmic drug recainam (10 mg/kg over 20 min followed by 10 mg/kg/h) were evaluated [9].

Analytical, diagnostic and therapeutic context of Recainam

• Effect of recainam on the energy required for ventricular defibrillation in dogs as assessed with implanted electrodes [14].
• Approximately 8.9% +/- 3.8% of a recainam dose was eliminated during a 4-hour hemodialysis period [5].
• Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias [15].
• Plasma and urine samples were collected during the 36-hour period after drug administration and analyzed for recainam concentrations by HPLC [7].
• Plasma recainam concentration was determined by high performance liquid chromatography (HPLC) [3].

References